Imagion Biosystems

Imagion Biosystems EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Imagion Biosystems (IBX.AX) as of Oct 22, 2026 is -2.48. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -7.48 — a change of -66.79% (higher).

EV/FCF

-2.48

YoY

-66.79%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Imagion Biosystems is 2025 -2.48 . EV/FCF (Enterprise Value to Free Cash Flow) of Imagion Biosystems was 2024 -7.48 . It decreases by -66.79% higher compared to the previous year.

The Imagion Biosystems EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-0.61 AUD
Jan 1, 2019
-1.62 AUD
Jan 1, 2020
0.69 AUD
Jan 1, 2021
0.76 AUD
Jan 1, 2022
-1.10 AUD
Jan 1, 2023
-1.78 AUD
Jan 1, 2024
-7.48 AUD
Jan 1, 2025
-2.48 AUD
The Imagion Biosystems EV/FCF history
YEAREV/FCFYoY
-2.48-66.79%
-7.48+320.20%
-1.78+61.04%
-1.10-245.05%
0.76+9.58%
0.69-142.89%
-1.62+165.84%
-0.61+77.11%
-0.34-98.07%
-17.80+342.47%
-4.02-25.42%
-5.39—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Imagion Biosystems Stock analysis

What does Imagion Biosystems do? Imagion Biosystems Ltd develops non-radioactive diagnostic imaging technology through its MagSense and PrecisionMRX product lines. MagSense uses cancer-specific magnetic nanoparticles for detecting breast, prostate, and ovarian cancers, with a Phase I clinical study ongoing for its HER2 imaging agent. PrecisionMRX offers coated nanoparticles including Dextran-Coated, mPEG Coated, Oleic Acid Coated, and Carboxylic Acid Functionalized variants for magnetic relaxometry applications. The company generates revenue primarily through research and development activities, focusing on advanced cancer diagnostics and medical imaging solutions. The firm operates exclusively in the Research and Development segment, targeting medical professionals and healthcare institutions requiring innovative diagnostic tools. MagSense technology is designed as an injectable solution tailored to specific cancer types, while PrecisionMRX nanoparticles serve biomedical applications demanding high precision. These products are developed for use in cancer diagnostics, with clinical studies validating their effectiveness in detecting critical diseases. Imagion Biosystems' revenue streams derive from the development and commercialization of its proprietary imaging technologies. The company's MagSense platform enables functional imaging for cancer detection without radioactive materials, appealing to healthcare providers seeking safer diagnostic alternatives. PrecisionMRX nanoparticles support specialized biomedical applications, offering customizable solutions for medical imaging needs across various cancer types. Imagion Biosystems is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imagion Biosystems stock

EV/FCF (Enterprise Value to Free Cash Flow) of Imagion Biosystems is -2.48 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Imagion Biosystems changed from -7.48 to -2.48, representing a -66.79% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Imagion Biosystems since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Imagion Biosystems with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Imagion Biosystems

All Key Metrics — Imagion Biosystems